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Abstract
In the processing of biopharmaceuticals, viral clearance and viral safety are important for 
the development of monoclonal antibodies. Murine xenotropic leukemia virus (XMuLV) is one 
of the retroviruses, recommended by Food and Drug Administration (FDA) as a model virus for 
viral clearance via inactivation from therapeutics derived from Chinese hamster ovary cells 
(CHO). A robust and effective method was investigated to clear or inactivate endogenous viruses 
by low pH inactivation. The effects of different conductivity and inactivated time on XMuLV 
clearance was determined.  Acetate buffer was prepared with different conductivity, and 2% 
XMuLV was spiked into acetate buffer. XMuLV virus particles could be effectively inactivated 
in acetate buffer at pH 3.6. According to TICD50 assay, the inactivation time of around 60 minutes
was enough to clear all the viruses with more than 4 logs reduction value (LRV). Also, 50 mM 
acetate buffer has the most rapid inactivation process. TICD50 assays were able to determine the 
XMuLV virus titer within 95% confidence level, by using 8 replicates and 10-fold series dilution 
factor. 
1. Introduction 
Biological and biochemical products have high risks of contamination from chemical 
impurities, bacteria, fungi, and the most dangerous one is from viruses. Viral contamination will 
affect raw materials, cell lines, cell culture process, and downstream processing (1). Thus, viral 
clearance and viral safety were critical for products produced by mammalian cells such as 
monoclonal antibodies (mAbs) because mammalian cells are highly sensitive to viral 
contamination by adventitious viruses. For example, Chinese hamster ovary cells (CHO) should 
express non-infectious retroviruses or retroviral-like particles during the production of 
therapeutics (2-3). As applying a virus inactivation method during downstream production, it 
could effectively eliminate concerns about underlying infectious, adventitious or dangerous 
agents. Commonly, two dedicated, virus clearance steps, such as viral removal and viral 
inactivation are included in the purification process. But virus inactivation processes are stable 
processes and less sensitive to minor factors than the viral removal process. As a result, virus 
inactivation is generally robust and effective (2,4). 
One of the effective inactivation methods is low pH inactivation, performed by spiking 
enveloped viruses such as XMuLV, pseudorabies Virus, and herpesviruses into the low pH 
solution, which provides at least 4 logs of virus clearance for these viruses (7-8). For mAbs and 
Fc fusion proteins production, acidified buffer always follows the inactivation, and these 
enveloped viruses should be hold statically in for at least over 30 minutes to completely damage 
the surface glycoproteins and prevent the viruses infecting the cells (8,9). At the end of 
inactivation holding times, the acidified buffer with viruses is neutralized to pH 7 (9,10).
In the process of viral inactivation, XMuLV is used as inactivation model virus, produced
by Mus Dunni cells and mink lung cells (5). As XMuLV is similar to gamma retrovirus, a 
nonmurine cell line PG-4 cell line is used to propagate the virus. PG-4 cells were astrocyte, 
moloney murine sarcoma virus transformed, using for detection and quantitation of replication 
competent retroviruses. PG-4 cells are resisted to infection and focus formation by ecotropic 
murine leukemia virus (5-6). 
2. Material and Methods 
PG-4 cells, McCoy’s 5A medium, fetal bovine serum (FBA) were purchased from 
American Type Culture Collection (ATCC, Manassas, VA). Penicillin/streptomycin solution 
(10,000 U/mL) was purchased from ATCC (Manassas, VA), stored at - 20oC . Sterile 
phosphate buffer saline without calcium and magnesium (PBS), and sodium acetate trihydrate 
(CH3COONa+3H2O) were purchased from VWR Scientific (Radnor, PA). 0.25% trypsin- 0.53 
mM EDTA solution(1X), trypan-blue (0.4%), and acetic acid (CH3CO2H) were purchased from 
Millipore Sigma (Burlington, MA) and kept frozen at - 20oC . Sterile deionized water (DI 
water) was collected through water Pro/RO reverse osmosis plus deionization purification 
system by Labconco Corp (Kansas City, MO). L-Glutamine in220mM solution (292 mg/mL-
Glutamine in 0.85% NaCl) was purchased from VWR scientific (PA). Tris base (C4H11NO3) was 
purchased from G-biosciences (St. Louis, MO). 
All the experiments were safely run inside the laminar flow cabinet. Different size of the 
serological pipettes and pipette tips as well as 15 and 50mL, sterile centrifuge tubes, micropipette
and sterile disposable pipette tips, 25 and 75 cm2 sterile cell culture flasks and 96-well flat-
bottom cell culture plate (sterile) were used in cell recovery, cell passaging and TCID50 assay. All
equipment was sprayed by 70% IPA before entering the hood. 
2.1 PG-4 Cell Line Recovery and Passaging 
2.1.1 PG-4 Cell Recovery 
McCoy’s 5A medium, L-Glutamine (LG), FBS were warmed up at 37oC  in a cell 
culture incubator with 5% CO2. Penicillin were thawed at room temperature without light under 
aluminum foil. Afterwards, a total of 20 mL of cell medium was prepared by adding in 20 mL of 
McCoy’s 5A medium with 1% LG, 2% FBS, and 0.01% penicillin was prepared in a 50 mL 
sterile centrifuge tube. A total of 5 mL of prepared medium was transferred into a 25 cm2 cell 
culture flask. A vial of frozen PG-4 cells was taken from the liquid nitrogen tank and thawed 
with  37oC  water bath, agitating back and forth with no more than 3 minutes. The warmed 
cell suspension was transferred into a 15 mL of medium drop by drop and mixed gently. After 
that, it was centrifuged at 1500 RPM for 5 minutes. A clear wall of cells attached on the 
centrifuge tube could be observed. The supernatant was removed from the other side of the wall 
carefully. The rest of 5 mL medium was resuspended into the cell pallet and transferred into 25 
cm2 flask. Finally, cells were kept in the cell culture incubator. 
2.1.2 PG-4 Cell Passaging 
A total of 30 mL of passaging medium was prepared in a 75 cm2 sterile cell culture flask 
with the same contents as the cell recovery medium. Afterwards, the old cells were taken and 
observed under the inverted light microscope to check if the cells reached 50-60% confluence. 
Using a 10 mL serological pipette to aspire all the old medium from the 25 cm2 flask for the cells 
to be passaged. 10 mL of sterile warm PBS was used to wash out the cell debris and remaining 
old medium. After that, 2.5-3 mL trypsin-EDTA (TE) was added to cell monolayers to detach the
cells. After incubating with TE for 3-5 minutes, cells were observed under microscope to check if
all the cells are single and floating. Then, 5 mL of complete medium was aspirated into the cell 
to disperse the cells. The cell suspension was then transferred into a 15 mL centrifuge tube and 
centrifuged at 130 xg for 5 minutes. After removing the supernatant, cells were suspended in 5 
mL of fresh complete medium. A designated number of cells were counted and transferred for 
the next passage with 20mL of medium remained in the flask (passage ratio at 1:4 to 1:10).
3. XMuLV Virus Inactivation in Low-pH Acetate Buffer 
3.1Acetate Buffer Preparation 
20, 50 and 100 mM acetate buffer solutions were prepared using 100 mL with DI water, 
appropriate amount of sodium acetate and acetic acid, at low pH 3.6 (Table 1). After pH and 
conductivity were measured, the acetate buffers were equilibrated in an incubator at 18 °C for 2 
hours. 
Table 1. Initial condition for preparing acetate buffers at different concentration
Buffer
Concentration(mM)
Sodium Acetate
(mg)
Acetate Acid
( μL )
20mM 17.61 107.08
50mM 44.03 267.07
100mM 88.05 535.41
3.2 Virus Propagation on PG-4 Cells and Virus Inactivation
After 2 hours of incubating, 100 mL acetate buffer was filtered with Millex-GP syringe 
filter. The filtered buffer was transferred into 100mL baker. A 40 mL filtered buffer was divided 
into tubes, containing 10 mL of buffer for each tube. These buffers were used to measure pH and 
conductivity after filtering. They were also used to test the amount of 1 M tris needed in order to 
increase the pH to 7. Then, this predetermined volume of 1M tris buffer was added into each of 
the six tubes for neutralizing virus-buffer sample later (Table 2). The rest 60 mL of buffer was 
spiked with 2% XMuLV virus. As the beginning of the kinetic study, 1.2 mL XMuLV virus was 
spiked into 60 mL buffer and mixed well. After 1 minute, two of 10 mL inactivated virus-buffer 
were transferred into the tubes, one for pH and conductivity control, one for determining the 
virus titre with 1M tris to terminate the inactivation process. Then, after 5, 15, 30, 60 minutes, 
each 10 mL of inactivated virus-buffer sample was pipetted into tubes contained with 1 M tris. 
Thereafter, inactivated XMuLV stock was diluted by 10-fold series dilution factor for titer 
determination using TCID50 assay. After seeding PG-4 cells for 24 hours, the cells were 
inoculated with diluted XMuLV stock by 8 replicates in 96 well plates. The cocultivation would 
last for 7 to 8 days. On day 7, the samples were ready for reading according to TCID50 assay.
Table 2. Initial pH and conductivity of acetate buffer for inactivation, and 1M tris added to
neutralize the pH and conductivity
Buffer
Concentration
 (mM)
Initial
pH
Initial
Conductivity
( μS/cm )
1M Tris
Neutralized
( μL )
Final
pH
Final
Conductivity
( μS/cm )
20 3.60 256 185ul 7.00 1141
50 3.61 773 490ul 7.01 2853
100 3.60 1100 970ul 7.00 4450
3.3 TCID50 Assay to Determine Virus Titre
On day 1, 100 μl  newly-made cell suspension was added to each well of 96-wells plate
and incubated at 37oC overnight. On day 2, after cells seeding were complete and reach the 20% 
confluency, all inactivated virus samples were assayed for XMuLV infectivity by using TCID50 
assay (3). Before TCID50 titration, all samples were diluted 10-fold series with fresh medium to 
eliminate cytotoxic effects. PG-4 cells were infected by 100 μl  of diluted samples on 96-well 
plates, including the inactivated samples and original virus stock. Virus titre, and 95% 
confidence level for the log titre of the virus stock were determined by method of Spearman-
kärber (4).
4. Results and Discussion
After 7-8 days, the plates were ready for evaluation; by distinguishing health PG-4 cells 
(Fig. 1a) or infected PG-4cells (Fig. 1b), the wells would be recorded as negative or positive. 
Also, PG-4 cells were infected by inactivated XMuLV viruses at 1, 5, 15, 30 and 60 minutes (Fig
1c-1g). For inactivation time below 15 minutes, there were plenty of regions under infection by 
XMuLV.  However, as the inactivation time increased, the infected region got smaller. Until 60 
minutes, it was no infected PG-4 cells exiting. Based on figure 1, inactivation time around 60 
minutes is enough to clear XMuLV virus, and TCID50 assay was not able to detect infection over 
60 minutes. 
Figure 1 Infected PG-4 cells on day 7. A) Negative control- health PG-4 cells. B) Positive
Control- infected by XMuLV virus. C)-D) infected PG-4 cells by inactivated XMuLV virus at
different time.
The pH and conductivity of control samples after being inactivated were measured to 
make sure the pH was still around the same range as the buffer, and pH slightly increased around
3.68 or 3.7 (Table 3). Also, virus tire and LRV were calculated with different inactivation kinetics
and shown in Table 4.
Table 3. pH and conductivity ( μS/cm ) measured after virus was spiked into 20, 50, and 
100 mM acetate buffer
Standard deviation and 95% confidence level indicated the accuracy and repeatable of 
TCID50 assay. Table 4 was shown sample with 20 mM acetate buffer, the average original virus 
stock titre was 5.92 logs/mL, during each inactivation time, the titre was decreased till 
1.58logs/mL. Until 60mins, TCID50 assay was not able to determine the infection of XMuLV 
virus. Also, the pooled standard deviation for all samples were less than 0.5 logs and resulted in 
95% confidence level less than 0.5 logs, and the variation within the assay didn’t exceed ± 0.5 
logs. Also, samples with 50mM and 100mM acetate buffer, and the original virus stock titre for 
both was calculated as 6.00 logs/mL, and for each inactivation kinetics, the average titre was 
decreased. Still, for 50mM kinetics, the pooled standard deviation for all samples was less than 
0.5 logs and resulted in 95% confidence level less than 0.5 logs, and the variation within the 
assay didn’t exceed ± 0.5 logs. Thus, initial precision experiments are proved that those assays 
were able to determine the XMuLV virus titre within 95% confidence level, by using 8 replicates
and 10-fold series dilution factor. However, for 100mM kinetics, the inactivation time at 5 
minutes, the standard deviation of 0.26 resulted in a 95% confidence level of 0.52 logs, and the 
variation within the assay exceeded ± 0.5 logs, thus, for more accurate determination, this 
kinetics with inactivation time at 5 minutes, should be repeated. 
Table 4. Log total virus in 10mL, Log reduced value (LRV), 95% confidence level for
20mM, 50mM, and 100mM Acetate buffer.
 
20mM 50mM 100mM
Time 
(Mins)
Total Virus 
(logs)
LRV Total Virus
(logs) 
LRV Total Virus
(logs) 
LRV
0 6.92±0.64 0.00 7.00±0.78 0.00 7.08±0.72 0.00
1 4.42±0.5 2.50 3.69±0.18 3.33 4.25±0.50 2.83
5 3.92±0.3 3.00 3.08±0.30 3.92 3.17±0.52 3.17
15 3.33±0.42 3.58 2.92±0.30 4.08 3.08±0.30 4.00
30 2.83±0.28 4.08 2.83±0.24 4.17 2.67±0.18 4.41
60 2.58±0.08 4.33 2.50±0.00 4.50 2.58±0.08 4.50
Log reduced value was used to determine the number of viruses eliminated from the 
inactivation kinetics. LRV was calculated by the equation LRV=log10((CF∗V f) /(C∗V ))
(11). Cf and Vf refer as original virus titre and original virus volume, in here is 10mL. C and V 
refers as filtrate virus titre and filtrated virus volume, still 10mL. After calculation, LRVs was 
determined by plotting the each LRV kinetics curve with inactivation time.  With long 
inactivation time, the curve was increased sharply and stay flat. At the beginning of 1-minute 
inactivation, 50mM inactivation kinetics had the most rapid increase on LRV, and for 20mM 
kinetics, it had smallest increase on LRVs (Fig. 2a) In addition, 50mM buffer has the most 
decreased on total amount of virus in 2.5 logs/10mL sample volume, and 20mM, 100mM has the
same decreased value, reaching 2.58 logs/10mL (Fig. 2b). Accordingly, for all of kinetics, around
60-minutes inactivation, there were no more XMuLV virus being detected, and LRVs reached 
4.50, which showed that most of XMuLV viruses were inactivated by the acetate buffer at pH 3.6
with different conductivity.  Thus, the final LRVs were greater than 4.0-4.5. Also, the inactivated 
kinetics were independent on the changing conductivity. 
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Figure 2 A) Trends for log reduced value with XMuLV virus being inactivated in different time.
B) Error bar for log total virus in 10mL inactivation buffer with different time
5. Conclusion 
The purpose of this project was to investigate the virus clearance method with low pH 
and determine if conductivity and inactivation duration had any effective impact on virus 
clearance. The entire work was performed by PG-4 cell line passaging and TCID50 assay to 
determine the virus titre and LRV (log reduced value). At pH 3.6, all of the kinetics had 
completed the inactivation process around 60-minutes. Also, standard deviation resulted in 95% 
confidence level within 0.5 logs, which proved that this inactivation kinetic was effective and 
accurate.  There were no more XMuLV being detected by TCID50 assay until 60 minutes.  For 60 
minutes inactivation, it was enough to obtain > 4 logs LRVs. 
In summary, XMuLV virus particles could be effectively inactivated in acetate buffer 
with different conductivity at pH 3.6. Also, inactivation efficiency was independent on changing 
conductivity and dependent on holding duration. However, based on data, 50mM acetate buffer 
A B
had the best inactivation on XMuLV virus particles. Furthermore, the kinetics over 60 minutes 
should be tested with other assays to check whether all the viruses got cleared. 
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